title: Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.
abstract: Twenty-three adolescents with psychotic disorders, aged from 13 to 18 years, participated in a 12-week open label trial (17 adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global Impression and Positive and Negative Symptom Scale (P's ≤ 0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed on one executive function (P = 0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction between quetiapine doses (>300 mg/day or <300 mg/day) and time, where lower doses showed more improvement in verbal short-term memory (P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12 weeks of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition abilities and verbal short-term memory) and on positive symptoms.
authors.affiliation: Unité de Recherche, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (SUPEA), Centre Hospitalier Universitaire Vaudois (CHUV), Route du Bugnon 25A, 1011, Lausanne, Switzerland. Sebastien.Urben@chuv.ch
authors.forename: Sébastien
authors.initials: S
authors.lastname: Urben
authors.forename: Pierre
authors.initials: P
authors.lastname: Baumann
authors.forename: Sandra
authors.initials: S
authors.lastname: Barcellona
authors.forename: Muriel
authors.initials: M
authors.lastname: Hafil
authors.forename: Ulrich
authors.initials: U
authors.lastname: Preuss
authors.forename: Claire
authors.initials: C
authors.lastname: Peter-Favre
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Clarke
authors.forename: Olivier
authors.initials: O
authors.lastname: Halfon
authors.forename: Laurent
authors.initials: L
authors.lastname: Holzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D018697:Nootropic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D018697:Nootropic Agents; D000069348:Quetiapine Fumarate
references.citation: Am J Psychiatry. 1997 Nov;154(11):1613-5
references.pmid: 9356577
references.citation: Biol Psychiatry. 2005 Nov 1;58(9):705-12
references.pmid: 16023084
references.citation: Cogn Psychol. 2000 Aug;41(1):49-100
references.pmid: 10945922
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Schizophr Res. 2000 Apr 7;42(2):135-44
references.pmid: 10742651
references.citation: Eur Psychiatry. 2004 Sep;19(6):384-6
references.pmid: 15363482
references.citation: J Clin Psychiatry. 2006 Jul;67(7):1093-103
references.pmid: 16889453
references.citation: J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):170-5
references.pmid: 12544176
references.citation: Schizophr Bull. 1994;20(4):647-69
references.pmid: 7701274
references.citation: Schizophr Bull. 2005 Jan;31(1):5-19
references.pmid: 15888422
references.citation: Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70
references.pmid: 17629731
references.citation: Br J Psychiatry Suppl. 2002 Sep;43:s45-9
references.pmid: 12271800
references.citation: Bipolar Disord. 2009 May;11(3):225-55
references.pmid: 19419382
references.citation: Arch Gen Psychiatry. 1997 Jun;54(6):549-57
references.pmid: 9193196
references.citation: Arch Gen Psychiatry. 2002 Nov;59(11):1053-60
references.pmid: 12418939
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):233-8
references.pmid: 15694229
references.citation: Am J Psychiatry. 1999 Apr;156(4):544-9
references.pmid: 10200732
references.citation: J Psychiatr Pract. 2007 Mar;13(2):86-96
references.pmid: 17414684
references.citation: Lancet. 2008 Mar 29;371(9618):1085-97
references.pmid: 18374841
references.citation: Am J Psychiatry. 1996 Mar;153(3):321-30
references.pmid: 8610818
references.citation: J Clin Psychopharmacol. 2010 Oct;30(5):496-503
references.pmid: 20814316
references.citation: Neuropsychopharmacology. 2008 Sep;33(10):2303-12
references.pmid: 18059438
references.citation: Neuropsychiatr Dis Treat. 2007 Apr;3(2):219-35
references.pmid: 19300555
references.citation: Paediatr Drugs. 2007;9(6):419-23
references.pmid: 18052412
references.citation: J Neural Transm (Vienna). 2003 May;110(5):545-60
references.pmid: 12721815
references.citation: Curr Opin Neurol. 2006 Dec;19(6):607-12
references.pmid: 17102701
references.citation: Arch Gen Psychiatry. 2002 Jan;59(1):25-30
references.pmid: 11779278
references.citation: J Child Adolesc Psychopharmacol. 2001 Winter;11(4):415-24
references.pmid: 11838824
references.citation: J Clin Psychiatry. 2010 Sep;71(9):1243-4
references.pmid: 20923625
references.citation: Psychiatry Res. 2011 May 15;187(1-2):49-54
references.pmid: 21075453
references.citation: Biol Psychiatry. 1997 Aug 15;42(4):233-46
references.pmid: 9270900
references.citation: Schizophr Res. 2007 Sep;95(1-3):48-53
references.pmid: 17629676
references.citation: Schizophr Bull. 2005 Jul;31(3):705-22
references.pmid: 16006592
references.citation: J Clin Psychopharmacol. 2003 Jun;23(3 Suppl 1):S15-20
references.pmid: 12832945
references.citation: Arch Gen Psychiatry. 2000 Jun;57(6):553-9
references.pmid: 10839333
references.citation: Pharmacopsychiatry. 2011 May;44(3):87-95
references.pmid: 21318938
references.citation: Eur Child Adolesc Psychiatry. 2009 Jul;18(7):418-28
references.pmid: 19198920
references.citation: Am J Psychiatry. 2000 Apr;157(4):514-20
references.pmid: 10739409
references.citation: Schizophr Res. 2002 Jan 15;53(3):239-48
references.pmid: 11738537
references.citation: J Clin Psychiatry. 1999;60 Suppl 8:21-8
references.pmid: 10335668
references.citation: Schizophr Bull. 2011 Mar;37(2):405-15
references.pmid: 19706697
references.citation: Psychiatry Res. 2004 Dec 30;129(3):241-7
references.pmid: 15661317
references.citation: Eur Psychiatry. 2005 Aug;20(5-6):395-402
references.pmid: 16171654
references.citation: J Clin Psychiatry. 2000 Apr;61(4):252-60
references.pmid: 10830145
references.citation: Int Clin Psychopharmacol. 2010 Jan;25(1):1-6
references.pmid: 19809337
references.citation: Addiction. 2001 Oct;96(10):1477-84
references.pmid: 11571066
references.citation: J Child Adolesc Psychopharmacol. 2008 Feb;18(1):54-69
references.pmid: 18294089
references.citation: Behav Pharmacol. 2000 Nov;11(7-8):639-42
references.pmid: 11198135